FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
nstruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kalb Michael Wayne						2. Issuer Name and Ticker or Trading Symbol AMARIN CORP PLC\UK [AMRN]										tionship of Reportin all applicable) Director Officer (give title		son(s) to Iss 10% Ov Other (s	wner
	(Last) (First) (Middle) C/O AMARIN PHARMA, INC. 440 US HIGHWAY 22						2020		saction (M				below) below) SVP and CFO						
,	EWATER N		08807		_ 4. If	Ame	endmer	nt, Date	of Origina	l Filed	(Month/D	ay/Year)		Line	Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		(Zip)									_				_			
Table I - Non-Deriv. 1. Title of Security (Instr. 3) 2. Transa Date (Month/L)					action	ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A)			A) or	5. Amou Securitie Benefici Owned I Reporte	nt of es ally Following d	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) (D)	or F	Price	Transac (Instr. 3				
Ordinary	Shares ⁽¹⁾			11/30	0/2020)			M ⁽²⁾		1,52	8 /	1	(3)	⁽³⁾ 101,861 ⁽⁴⁾ Γ				
Ordinary	Shares ⁽¹⁾			11/30	0/2020)			M ⁽²⁾		1,52	8 /	1	(3)	103	103,389 D			
Ordinary	Shares ⁽¹⁾			11/30	0/2020)			F ⁽⁵⁾		1,49	8 I		\$4.6	101,	891(6)	D		
		Т									osed of onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr 8)		n of		6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal	ole E	expiration pate	Title	or Nur of	mber ares					
Restricted Stock Units ⁽⁷⁾	\$0.00	11/30/2020			M			1,528	(2)		(3)	Ordinar Shares ⁽¹		528	\$0.00	13,749	9	D	
Restricted Stock Units ⁽⁷⁾	\$0.00	11/30/2020			M			1,528	(2)		(3)	Ordinar Shares ⁽¹		528	\$0.00	13,749	9	D	

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 220,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding \$400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-seventh vesting event occurred on November 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches
- 3. Not applicable.
- 4. Includes 1,862 shares purchased under the Issuer's 2017 Employee Stock Purchase Plan on November 30, 2020.
- 5. Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
- 6. Please see the section titled "Remarks" below for additional information.
- 7. Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.

As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 927,255 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and RSUs granted under the Plan, including but not limited to certain performance-based RSUs that are earned only if product revenues reach pre-defined annual milestone levels and, in certain cases, then vest only if the recipient remains with the company for an extended period of time.

> /s/ Joseph T. Kennedy, by 12/02/2020 power of attorney

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.